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Abstract: Pancreatic cancer has the worst prognosis and lowest survival rate among all cancers. Pancreatic cancer cells are highly metabolically active and typically reprogrammed for aberrant glucose
metabolism; thus they respond poorly to therapeutic modalities. It is highly imperative to understand
mechanisms that are responsible for high glucose metabolism and identify natural/synthetic agents
that can repress glucose metabolic machinery in pancreatic cancer cells, to improve the therapeutic
outcomes/management of pancreatic cancer patients. We have identified a glycoside, steviol that
effectively represses glucose consumption in pancreatic cancer cells via the inhibition of the translation initiation machinery of the molecular components. Herein, we report that steviol effectively
inhibits the glucose uptake and lactate production in pancreatic cancer cells (AsPC1 and HPAF-II).
The growth, colonization, and invasion characteristics of pancreatic cancer cells were also determined
by in vitro functional assay. Steviol treatment also inhibited the tumorigenic and metastatic potential
of human pancreatic cancer cells by inducing apoptosis and cell cycle arrest in the G1/M phase. The
metabolic shift by steviol was mediated through the repression of the phosphorylation of mTOR and
translation initiation proteins (4E-BP1, eIF4e, eIF4B, and eIF4G). Overall, the results of this study
suggest that steviol can effectively suppress the glucose metabolism and translation initiation in
pancreatic cancer cells to mitigate their aggressiveness. This study might help in the design of newer
combination therapeutic strategies for pancreatic cancer treatment.
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1. Introduction

published maps and institutional affil-

Pancreatic cancer (PanCa) is one of the most dangerous malignancies and is the source
of numerous deaths worldwide [1]. In addition to the lack of early diagnosis, the highly
metabolically active nature of pancreatic tumors leads to poor therapeutic outcomes, chemoresistance, metastatic phenotype, and aggressive behavior of the disease [2]. Therefore, it
is essential to investigate the underlying molecular mechanisms that are associated with
aberrant tumor metabolisms and identify natural/synthetic molecules that can reduce
metabolic behaviors of the pancreatic tumors/tumor cells. These studies may be highly
useful for improving the survival rate of pancreatic cancer patients.
In this study, we have identified steviol, a colonic metabolite of the natural sweetener
steviol glycoside, which can effectively alter the glucose metabolism of pancreatic cancer
cells. Steviol glycoside (stevioside) is obtained from the leaves of the Stevia rebaudiana
plant (Figure 1Ai). It has a low calorie content and is 300 times sweeter than sucrose.

iations.
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are highly responsible for driving pancreatic cancer translational machinery and lead to
aggressive metastatic tumors [18]. In addition, the chemo-resistant tumor cells need more
glucose for their survival and continuous growth. Therefore, novel therapeutic strategies
targeting glucose metabolism and the translation machinery are highly desired [19].
Different pathways can drive cancer aggressiveness and lead to metastasis [20]. Many
molecules involved in translation are regulated through signaling events that require the
mammalian target of rapamycin (mTOR). These include eukaryotic initiation factor 4Ebinding proteins (4E-BPs) and S6 protein kinases, which are both repressors of translation
proteins. In pancreatic cancer, the positive regulation of mTOR signaling hypophosphorylates 4E-BPs and activates S6 kinases, which leads to the initiation of translation process [21].
However, the molecular mechanisms by which amino acids modulate mTOR signaling
remain unclear. Protein synthesis requires the cell’s metabolic energy and glucose as a fuel
in high amounts, which is an important driver of mTOR pathway in cancer. 4E-BP regulates
eIF4E to form the cap-binding complex, the Eukaryotic initiation factor 4F (eIF4F). The
hypophosphorylation of 4EBP1 sequestrates eIF4E and prevents the interaction with eIF4G,
thereby inhibiting translation process [21]. 4E-BP proteins and eIF4G share the competitive
binding site to eIF4E. Furthermore, 4EBP1 works as an inhibitor of the cap-dependent
translation. Translation-related proteins are mostly abnormal in tumors, such as mTOR
and eIF4F, and result in the malignant phenotype, including immune escape, apoptosis
inhibition, and energetic metabolism deregulating. Chemotherapeutic drugs targeting
protein translation machinery to overcome cancer demonstrate improved outcomes in
several cancer types in clinical trials [22] as the development of therapeutic agents that
disrupt translation can control proliferation, drug resistance, and metastasis.
Therefore, targeting these molecules could be important for cancer treatment. One of
the biggest challenges in pancreatic cancer therapeutics is preventing tumor relapse [23].
Following tumor resection, pancreatic cells being highly aggressive; the reviving of even
a single cell can result in the recurrence of a tumor in the pancreas within a very short
time [24]. In addition to the chemotherapies that follow surgical tumor resection, continued
management of pancreatic tumor patients is desperately required to prevent tumor relapse
in patients [25]. Given the scenario, therapeutic interventions using natural dietary constituents would be the best option as the possibility of toxicity or serious side effects will
be comparatively minimal [26]. Therefore, this study investigates steviol for its ability to
target pancreatic tumors and the regulatory proteins that govern protein translation, tumor
proliferation, aggressiveness, and improve survival. Furthermore, we sought to understand
the anticancer effects of steviol in pancreatic cancer cells and uncover its mechanism of
action in pancreatic cancer. Our findings suggest that steviol modulating proliferation in
pancreatic cancer cells may be attributed to its role in regulating glucose metabolism and
protein translation and that it may act as a new treatment paradigm for pancreatic cancer
management in patients. Overall, this study illustrates that steviol could be a promising
candidate for therapeutic intervention, either alone or in combination strategies.
2. Materials and Methods
2.1. Cell Culture
The human pancreatic cancer cells (HPAF-II and AsPC1) used for this study were
obtained from ATCC culture collection. These cells were maintained in DMEM/F12 or
RPMI media, respectively, containing 10% fetal bovine serum which was supplemented
with 10% FBS (Atlanta Biologicals, Flowery Branch, GA, USA) and antibiotic/antimycotic
solution at 37 ◦ C in a humidified atmosphere (5% CO2 and 95% air atmosphere).
2.2. Antibodies
Primary antibodies from Cell Signaling Technology were used to analyze the expression of important proteins, Bcl-2 (catalog #4223S), Bax (catalog #2772S), Bcl-xL (catalog
#2764S), eIF4e (catalog #9742S), peIF4e (catalog #9741S), 4EBP1 (catalog #9452S), p4EBP1
(catalog #2855S), mTOR (catalog #4517S), p-mTOR (catalog #5536S), eIF4B (catalog #3592S),
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peIF4B (catalog #3591S), eIF4G (catalog #2498S), peIF4G (catalog #2441S), p18 (catalog
#2896S) and p21 (catalog #2947S). Cleaved PARP (sc-8007) and Cyclin D1 (sc-753) antibodies were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). β-actin antibody was
obtained from Sigma (catalog #A2228; St. Louis, MO, USA). The horseradish peroxidase
conjugated rabbit (catalog #4011) and mouse (catalog #4021) secondary antibodies were
procured from Promega (Madison, WI, USA).
2.3. Proliferation Assay
Pancreatic cancer cell lines were seeded at 5000 per well in 96-well plates and allowed
to attach overnight. The following day, cells were treated with different concentrations of
steviol for 48 h. MTT assays were performed to determine the antiproliferative potential of
steviol on pancreatic cancer cells. Assays were terminated by adding 20 µL of MTT reagent
to the cells. After 2 h of incubation, 100 µL of DMSO was added to the cells, then the plates
were kept on a shaker for 10 min and the absorbance was recorded at 570 nm.
2.4. Western Blotting
Cell lysates were prepared and immunoblotting was performed [27]. Control and
steviol-treated samples were loaded on a gradient gel (4–20%), transferred onto a PVDF
membrane, and immunoblotted with respective antibodies after blocking in 5% milk. The
secondary antibodies were added after washing the membranes with 1X TBST buffer, and
the blots were developed with an ECL solution on a UVP machine.
2.5. Clonogenic Assay
Cells (250) were seeded in 12-well plates and grown for 4 days to form colonies [28,29].
The treatment was performed as soon as colonies started to appear. The experiment was
terminated following 15 days of treatment and after washing, fixing with cold methanol,
cells were stained with crystal violet and imaged.
2.6. Real-Time xCELLigence Assays
To analyze the cell growth and migration inhibitory effects of steviol on pancreatic
cancer cells, real-time proliferation and migration assays were conducted with the help
of a xCELLigence instrument as described in our recently published studies [30]. Cells
were seeded on the respective plates and were incubated in a 37 ◦ C incubator with 5% CO2
condition. The experiment was terminated at the indicated time points and the results
were analyzed.
2.7. Migration Assay
Cell migration assay was performed using Boyden chamber assay [31]. Cells
(5 × 104 /well) were seeded in a 96-well plate on the upper chamber with media devoid of serum while the lower chamber contained 250 µL of media with serum. The
cells were treated with steviol at different concentrations for 18 h and then fixed with
4% paraformaldehyde, followed by staining using crystal violet reagent. Thereafter, the
plate was washed using tap water, air dried, and the images were captured for data
analysis/quantification.
2.8. Invasion Assay
The cell invasion assay was conducted using Matrigel Invasion Chambers obtained
from BD Biosciences as described earlier [31]. The chambers were hydrated for 2 h in
serum-free media. Furthermore, the cells were seeded (25 × 104 /chamber) in 500 µL of
serum-free media. The next day, the cells were treated with steviol at various concentrations
in the chamber for 24 h. Cells were fixed using cold methanol, and staining was performed
using crystal violet reagent. After washing and air-drying, images were captured for
data analysis.
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2.9. Cell Cycle Studies
This assay was performed through the Telford method as described earlier [32]. Briefly,
cells were seeded (0.5 × 106 ) in a 6-well plates, incubated overnight, and then treated with
steviol for 12 h and 24 h. The cells were trypsinized, washed with PBS, and fixed with 70%
ethanol. Furthermore, cells were incubated at 4 ◦ C for 1 h and later stained with propidium
iodide (PI) for about 4 h in the dark (at 4 ◦ C). Cell-cycle analyses were performed in FL2
channel using a flow cytometer and ModFit analysis software.
2.10. Lactate Assay/ Glucose Assay
Both assays were conducted as described in our previous publication [27]. Cells were
treated at described concentrations of steviol and glucose; lactate assays were conducted
following the instructions mentioned in the kits (Cayman Chemicals, Ann Arbor, MI, USA).
Thereafter, the absorbance readings were recorded, followed by plotting of the respective
graphs based on the calculations.
2.11. Statistical Analysis
The statistical analysis for this manuscript was conducted by Student’s t-test. The
p-values < 0.05 were regarded as statistically significant.
3. Results
3.1. Growth Inhibitory Effects of Steviol in Pancreatic Cancer Cells
To investigate the anti-tumorigenic properties of steviol, functional assays were performed in HPAF-II and AsPC1 pancreatic cancer cells. Cells were treated with steviol at
various concentrations for 48 h. Both cell lines showed an inhibition of cell proliferation in
a dose-dependent manner, with a significant inhibitory effect at 10 mM (HPAF-II; control
vs. steviol 10 mM: 100 ± 1.57 vs. 54.8 ± 0.5 and AsPC1: 102.36 ± 3.91 vs. 53.54 ± 0.33) and
15 mM doses (HPAF-II; control vs. steviol 15 mM: 100 ± 1.57 vs. 48.05 ± 0.38 and AsPC1:
102.36 ± 3.91 vs. 40.9 ± 0.57) (Figure 1Bi,ii). Further, the suppression of proliferation in
HPAF-II cells was also evaluated by xCELLigence assay after the treatment with steviol
(Figure 1C). In addition, colony formation assays were performed to assess the long-term
effect of steviol. The ability to form colonies is a crucial characteristics of cancer cells.
The colony forming abilities of pancreatic cancer cells (AsPC1 and HPAF-II cells) were
significantly suppressed by steviol as compared to the untreated cells (Figure 1Di,ii). These
results demonstrated that steviol efficiently inhibited the growth and clonogenicity of
pancreatic cancer cells.
3.2. Steviol Suppresses Migration and Invasion Capabilities of Pancreatic Cancer Cells
Pancreatic cancer cells were treated with steviol at various concentrations, and it
was observed that steviol efficiently inhibited the cell invasion (Figure 2Ai,ii) and cell
migration (Figure 2Bi,ii) abilities in a dose-dependent manner. Moreover, the suppression
of migration in HPAF-II cells was evaluated by xCELLigence assay after treatment with
steviol. This also demonstrated that steviol is effective in repressing the cell invasion and
migratory potential of pancreatic cancer cells (Figure 2C).
3.3. Steviol Regulates Cell Cycle Machinery
Regulation of the cell cycle is an important mechanism of many drugs. Therefore, to
investigate the effect of steviol on cell-cycle regulation, pancreatic cancer cells were treated
with steviol for different time points (0, 12, and 24 h) for cell-cycle analyses. It was observed
that steviol induced G1 arrest, as depicted through the histogram graphs. The quantitative
G1 population with respect to time is represented in HPAF-II and AsPC1 cells (Figure 3A,B).
The proportion of G1 cells increased by about 27% in HPAF-II cells, and around 18% in
AsPC1 cells after 24 h of steviol treatment. Furthermore, to understand the underlying
mechanism of the G1 phase arrest, the regulatory proteins that are associated with the
G1 stage of cell cycle were evaluated to determine if steviol induced any inhibitory effects on

Biomedicines 2021, 9, 1814

6 of 15

them. Interestingly, the immunoblotting results demonstrated that the inhibitory proteins
associated with cell cycle, mainly p 18 and p 21, were significantly increased upon steviol
treatment. On the other hand, Cyclin D1, which is critically involved in the progression of
cell cycle [33], was remarkably downregulated in the presence of steviol in comparison to
Biomedicines 2021, 9, x FOR PEER REVIEW
6 of 16
the untreated/control cells. These observations suggest that steviol treatment can regulate
the cell cycle via the modulation of cycle-associated proteins (Figure 3Ci,ii).
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(a marker for early apoptosis) was observed after the treatment with steviol. These results
collectively indicated that steviol facilitates the apoptosis process in7 ofpancreatic
cancer cells
17
(Figure 4Ai,ii).
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(β-actin).
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6, and 9 h). It was observed that the expression of Bax protein (pro-apoptotic) was upregulated in both HPAF-II and AsPC1 cell lines while the expression of important anti-apoptotic proteins (Bcl-2 and Bcl-xL) decreased significantly in a dose-dependent manner. In
addition, increased PARP cleavage (a marker for early apoptosis) was observed after the
treatment with steviol. These results collectively indicated that steviol facilitates the apop8 of 15
tosis process in pancreatic cancer cells (Figure 4Ai,ii).

Figure
4. Steviol
inhibits
apoptosis
in pancreatic
cancer
cells.
expression
level
of important
Figure
4. Steviol
inhibits
apoptosis
in pancreatic
cancer
cells.
(A) (A)
TheThe
expression
level
of important
proteins
associated
with
apoptotic
pathway
waswas
evaluated
in HPAF-II
(Ai)(Ai)
andand
AsPC1
cellscells
(Aii)
of of
proteins
associated
with
apoptotic
pathway
evaluated
in HPAF-II
AsPC1
(Aii)
pancreatic
cancer.
Pancreatic
cancer
cells
were
treated
with
steviol
pancreatic
cancer.
Pancreatic
cancer
cells
were
treated
with
steviol(10
(10mM)
mM)atatdifferent
differenttime
timepoints
points (0,
(0, 3,3,6,6,and
and99h),
h),and
andWestern
Westernblotting
blottingwas
wasconducted
conductedafter
afterpreparation
preparationof
ofcell
celllysates.
lysates.Quantification
Quantification of
of blots
with
respect
to
the
loading
control
(β-actin)
was
performed
as
depicted
numbers
blots with respect to the loading control (β-actin) was performed as depicted byby
thethe
numbers
above
above the bands.
the bands.

3.5.3.5.
Steviol
Suppresses
Translation
Initiation
in Pancreatic
Cancer
Cells
Steviol
Suppresses
Translation
Initiation
in Pancreatic
Cancer
Cells
Disruption
in
the
translation
initiation
machinery
directly
relates
to carcinogenesis,
Disruption in the translation initiation machinery directly relates
to carcinogenesis,
andand
various
oncogenic
molecules
and tumor
suppressors
play aplay
major
role inrole
thisin
process
various
oncogenic
molecules
and tumor
suppressors
a major
this pro[36].cess
Therefore,
it was imperative
to understand
the mechanism
of actionof
ofaction
steviolofinsteviol
re[36]. Therefore,
it was imperative
to understand
the mechanism
lation
to the translation
initiation
pathways.
The expression
of proteins
associated
with
in relation
to the translation
initiation
pathways.
The expression
of proteins
associated
with translation
was analyzed,
the treatment
of pancreatic
cancer
with
translation
was analyzed,
after the after
treatment
of pancreatic
cancer cells
withcells
steviol
at steviol
difat different
time intervals.
Interestingly,
we observed
a remarkable
effect of
ferent
time intervals.
Interestingly,
we observed
a remarkable
inhibitoryinhibitory
effect of steviol
on the expression
of (peIF4E,
proteins (peIF4E,
peIF4B, peIF4G,
and p-mTOR)
on steviol
the expression
of proteins
peIF4B, peIF4G,
p4EBP1,p4EBP1,
and p-mTOR)
that arethat
are
involved
in
the
process
of
translation
initiation
(Figure
5Ai,ii).
These
proteins
involved in the process of translation initiation (Figure 5Ai,ii). These proteins are requiredare
required for the proper functioning of the translation initiation process. Steviol treatment
clearly inhibited the expression of these essential proteins, which in turn hampered the
formation of new proteins. It has been documented that activation of eIF4E increases the
key tumorigenic mRNAs translation in order to enhance oncogenic characteristics [37], and
steviol effectively decreased its phosphorylation. This suggest that steviol might delay the
translation initiation process, which in turn reduces the tumorigenic activity of pancreatic
cancer cells.
3.6. Steviol Decreases Glucose Uptake and Lactate Secretion in Pancreatic Cancer Cells
Pancreatic cancer cells consume a very high level of glucose, which is metabolized by the glycolysis pathway, and produce lactate as the final product of glucose
metabolism [27,38]. Therefore, we investigated if steviol could lower the glucose uptake and lactate production in pancreatic cancer cells. Indeed, steviol decreased lactate
secretion in both HPAF-II (control vs. steviol 10 mM: 6.45 ± 0.05 µM vs. 2.01 ± 0.08 µM)
and AsPC1 (9.49 ± 0.18 µM vs. 6.78 ± 0.26 µM) cell lines (Figure 6Ai,ii). Moreover, tumor
cells undergo altered metabolism to support and sustain their upregulated growth and
proliferative capabilities [27,38]. Studies have reported the potent anti-glycemic activity
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sor in rats and humans [11,12]. Thus, we examined its effect on glucose uptake/total glucose levels in pancreatic cancer cells. Interestingly, it is observed that steviol treatment (10
mM) significantly reduced glucose uptake/consumption in pancreatic cancer cells (HPAFII: 266.51 ± 1.0 mg/dL vs. 301.69 ± 1.65 mg/dL; and AsPC1: 134.21 ± 1.57 mg/dL vs. 207.14
± 4.24 mg/dL) as compared to untreated control cells (Figure 6Bi-ii). These findings10clearly
of 15
suggest that steviol can be a useful compound to lower glucose metabolism and lactate
production in pancreatic cancer cells.
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of steviol on glucose uptake by pancreatic cells as determined by glucose colorimetric assay kit after 48 h of steviol treatment
steviol treatment (Cayman Chemicals, Ann Arbor, MI, USA). Bar graphs represent the unused glucose in HPAF-II (Bi)
(Cayman Chemicals, Ann Arbor, MI, USA). Bar graphs represent the unused glucose in HPAF-II (Bi) and AsPC1 (Bii) cells.
and AsPC1 (Bii) cells. n = 2.
n = 2; * p < 0.05.

4. Discussion
Pancreatic cancer is the most dreadful disease among various cancers, and its incidence/mortality rates are rising across the globe [39]. Pancreatic cancer cells are typically
highly metabolically active [40]; as a result, the efficacy of current therapeutic options, including Gemcitabine (Gem), is very limited for the treatment of pancreatic cancer, currently
the most widely used [41–43]. The Warburg effect supports increased glucose intake by pancreatic cancer cells to meet pathogenic requirements [19,27]. Several oncogenes and tumor
suppressors have been shown to modulate metabolic reprogramming in pancreatic cancer
including PI3K/Akt/mTOR pathways [44]. Accumulating studies have shown that these
cell survival pathways are associated with translation initiation apparatus [45,46]. Hence,
it is highly imperative to identify drugs/molecules that can effectively modulate metabolic
reprogramming of pancreatic cancer cells. In this study, we have described a molecule,
steviol, that can effectively alter metabolic activities and inhibit protein translation in
pancreatic cancer cells.
Steviol is a natural compound with several beneficial properties including its sweet
taste, low toxicity, and that is safe for human use. Since 2011, it has been approved for use
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in the food sector, and their safety has been assessed by several bodies, including the World
Health Organization (WHO), and an ADI (Acceptable Daily Intake) [47,48]. Long-term
human trials have been performed to assess the effect of orally administered stevioside
at doses of 200–1500 mg/day [48]. Studies have also suggested its role as an anti-diabetic
as well as anti-inflammatory, and anti-cancer roles [14,49]. Our studies demonstrate the
growth inhibitory action of steviol in human pancreatic cancer (HPAF-II and AsPC1)
cells via inducing apoptosis, as indicated by PARP cleavage and upregulation in Bax and
inhibition in Bcl-2 and Bcl-xl. Steviol arrests cell-cycle progression in the G1 phase and
lowers the glucose uptake/lactate production in pancreatic cancer cells. Additionally,
steviol affected the expression of the key components of translation initiation machinery in
pancreatic cancer cells (HPAF-II and AsPC1).
A growing body of evidence suggests that abnormal activation of translation initiation
factors can result in malignant transformation and maintenance of altered phenotypes
in several human cancers [50–54]. Increased signaling flux from eIF4F activation causes
deregulated translation initiation, which is implicated in cancer initiation and progression [55,56]. It is observed that a number of angiogenesis factors and oncoproteins, as well
as pro-survival proteins and proteins involved in cancer invasion and metastasis, are all
found to be affected by increased assembly of the eIF4F translation initiation complex [57].
The eIF4E is required for the assembly of the eIF4F complex and is bound to the eIF4E
binding proteins (4EBPs) under normal conditions.
The 4EBP1 protein suppresses eIF4F formation by competing with eIF4G for eIF4E
binding. Abnormal eIF4E expression has been linked to cancer susceptibility and malignant
transformation [58,59]. Therefore, targeting eIF4F translation initiation complex might be
an ideal strategy for anti-cancer drug research for pancreatic cancer patients. Interestingly,
steviol treatment increased the expression of p4EBP1 protein in pancreatic cancer cells.
Therefore, we further sought to investigate the changes in expression level of the other key
proteins that are involved in the translation initiation process. We observed repression of the
key translation initiation proteins (peIF4E, peIF4B, peIF4G, and p-mTOR) in steviol-treated
pancreatic cancer cells. These proteins are strongly associated with the translation-initiation
process in eukaryotic cells [58,59]. Owing to their crucial roles in energy metabolism, which
is an essential feature of pancreatic cancer cells, steviol treatment probably led to a decrease
in the glucose uptake lactate secretion in pancreatic cancer cells. These results are consistent
with the findings by Chen et al. (2016), who reported the growth of an inhibitory effect of
steviolbioside in human pancreatic cancer cells [60]. Therefore, our findings delineate that
steviol might be a potent compound that can induce a metabolic shift in pancreatic tumors
(Figure 7). Although there are some concerns for its toxic effects on lymphocytes [61] and a
lack of significant reduction of pancreatic acinar carcinoma development by stevia extract
(0.02% w/v) in a murine model [62], more research into their efficacy and bioavailability
is warranted.
In conclusion, this study has investigated a dietary constituent, steviol, for its ability
to target pancreatic tumor and the regulatory proteins that govern protein translation and
tumor proliferation and aggressiveness (Figure 7). Steviol, being safe for human use, can
be considered as an effective modality for controlling glucose metabolism and regulating protein translation. Therefore, this study provides an important insight regarding
management of pancreatic cancer patients to prevent relapse and recurrence of tumors.
Additionally, it can help in improving therapeutic outcomes of frontline chemotherapeutic
drugs when used in combination. This strategy can enhance the survival of pancreatic
cancer patients; however, advanced clinical research in this direction is warranted to fully
support this notion.
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